KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) Invested Capital (2016 - 2026)

Travere Therapeutics filings provide 16 years of Invested Capital readings, the most recent being $98.7 million for Q1 2026.

  • On a quarterly basis, Invested Capital fell 2.81% to $98.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $98.7 million, a 2.81% decrease, with the full-year FY2025 number at $114.8 million, down 10.12% from a year prior.
  • Invested Capital hit $98.7 million in Q1 2026 for Travere Therapeutics, down from $114.8 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $279.8 million in Q3 2023 to a low of $15.1 million in Q2 2024.
  • Median Invested Capital over the past 5 years was $108.0 million (2022), compared with a mean of $122.5 million.
  • Biggest five-year swings in Invested Capital: crashed 87.72% in 2024 and later surged 570.66% in 2025.
  • Travere Therapeutics' Invested Capital stood at $49.9 million in 2022, then soared by 302.82% to $200.8 million in 2023, then crashed by 36.38% to $127.8 million in 2024, then dropped by 10.12% to $114.8 million in 2025, then dropped by 14.02% to $98.7 million in 2026.
  • The last three reported values for Invested Capital were $98.7 million (Q1 2026), $114.8 million (Q4 2025), and $73.6 million (Q3 2025) per Business Quant data.